Wegovy (semaglutide) is a prescription medication available as a once-weekly subcutaneous injection or a once-daily oral tablet. It is approved for chronic weight management, reducing cardiovascular risks in adults with heart disease and obesity or overweight, and treating specific liver conditions like MASH.
- Chronic Weight Management: Indicated for adults and pediatric patients aged 12 and older with obesity (BMI ≥ 30), or overweight (BMI ≥ 27) with weight-related comorbidities like high blood pressure, type 2 diabetes, or high cholesterol.
- Cardiovascular Risk Reduction: Lowers the risk of major adverse cardiac events such as stroke, heart attack, or cardiovascular death in adults with established heart disease and obesity or overweight.
Administration Options
- Injections: Self-administered subcutaneously once a week on the same day, regardless of meals.
- Pills: Taken once daily in the morning on an empty stomach with a small sip of water, waiting at least 30 minutes before eating, drinking, or taking other oral medications.
- Dose Escalation: Both formulations begin at a low dose that is gradually increased over several months to minimize gastrointestinal side effects.
Potential Side Effects and Safety- Common Side Effects: Nausea, vomiting, diarrhea, constipation, stomach pain, headache, and fatigue.
- Serious Risks: Carries a boxed warning for thyroid C-cell tumors based on animal studies. It is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). [



Reviews
There are no reviews yet.